English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/168865
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors

AuthorsNieto-Jiménez, Cristina; Alcaraz-Sanabria, Ana; Pérez-Peña, Javier; Corrales-Sánchez, Verónica; Serrano-Heras, Gemma CSIC ORCID; Galán-Moya, Eva María; Serrano-Oviedo, Leticia; Montero, Juan Carlos CSIC ORCID; Burgos, Miguel; Llopis, Juan; Pandiella, Atanasio CSIC ORCID CVN ; Ocaña, Alberto
KeywordsBreast cancer
BET inhibitors
Polo-like kinases
Triple negative breast cancer
Issue Date2017
PublisherImpact Journals
CitationOncotarget 8(12): 19478-19490 (2017)
AbstractMetastatic triple negative breast cancer (TNBC) is an incurable disease with limited therapeutic options, and no targeted therapies available. Triple negative tumors and the basal-like genomic subtype, are both characterized by a high proliferation rate and an increase in cell division. In this context, protein kinases involved in the mitotic formation have a relevant role in this tumor subtype. Recently, Bromodomain and extraterminal domain (BET) inhibitors have shown to be active in this disease by modulating the expression of several transcription factors. In this article, by using an >in silico> approach, we identified genomic functions that can be inhibited pharmacologically in basal-like tumors. Functional annotation analyses identified >cell division> and >regulation of transcription> as upregulated functions. When focus on cell division, we identified the polo-like kinase 1 (PLK) as an upregulated kinase. The PLK inhibitor Volasertib had the strongest anti-proliferative effect compared with other inhibitors against mitotic kinases. Gene expression analyses demonstrated that the BET inhibitor JQ1 reduced the expression of kinases involved in cell division, and synergized with Volasertib in a panel of triple negative cell lines. Combination of both agents augmented cell death. Similarly, combination of both compounds reduced the expression of stem cell markers. Globally, this data demonstrates the synergistic interaction between BET and PLK inhibitors, paving the way for their future clinical development.
Publisher version (URL)https://doi.org/10.18632/oncotarget.14465
Identifiersdoi: 10.18632/oncotarget.14465
e-issn: 1949-2553
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
targetinhibi.pdf5,16 MBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.